Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis

BACKGROUND: Pembrolizumab is a new drug approved in several countries for second-line therapy in non-small cell lung cancer (NSCLC) being programmed cell death ligand (PD-L1) positive. This drug has a high cost, and the cost-effectiveness ratio has been debated. PATIENTS AND METHODS: The budget impa...

Descripción completa

Detalles Bibliográficos
Autores principales: Norum, Jan, Antonsen, Margareth Aarag, Tollåli, Terje, Al-Shibli, Khalid, Andersen, Gry, Svanqvist, Kristin Helene, Helbekkmo, Nina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703383/
https://www.ncbi.nlm.nih.gov/pubmed/29209527
http://dx.doi.org/10.1136/esmoopen-2017-000222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703383/
https://www.ncbi.nlm.nih.gov/pubmed/29209527
http://dx.doi.org/10.1136/esmoopen-2017-000222

Ejemplares similares